Advanced Enzyme Technologies Ltd. Reports Mixed Q1 FY27 Results

Revenue for Q1 FY27 stood at Rs 189.8 crore, a 2% year-on-year increase.
Net profit after tax (PAT) saw a 5% year-on-year decline to Rs 38.6 crore.

Reader Takeaway: Revenue growth overshadowed by profit dip and margin pressure.

What just happened

Advanced Enzyme Technologies Ltd. announced its financial results for the first quarter of fiscal year 2027 (Q1 FY27). The company reported a consolidated revenue of Rs 189.8 crore, marking a marginal 2% increase compared to Rs 185.9 crore in the same quarter last year. However, profit after tax (PAT) declined by 5% to Rs 38.6 crore from Rs 40.4 crore in Q1 FY26. EBITDA also fell by 10% to Rs 51 crore from Rs 56.4 crore.

Why this matters

The mixed results indicate pressure on profitability despite modest revenue growth. The decline in margins, with EBITDA margin at 27% compared to 30% in the prior year, is a key concern for investors. This performance impacts shareholder value by reducing earnings per share and potentially affecting future dividend payouts.

The backstory

Advanced Enzyme Technologies is a leading enzyme manufacturer. The company has been focusing on expanding its product portfolio and market reach. In recent periods, it has also undertaken strategic corporate actions to consolidate its position and return value to shareholders.

What changes now

Following the Q1 FY27 results, the company has approved a buyback of its shares worth Rs 69.7 crore at a price of Rs 500 per share. Additionally, it has acquired the remaining 4.28% stake in JC Biotech for Rs 7.98 crore, gaining full control. These actions signal management's confidence in the company's financial health and future prospects.

Risks to watch

Key risks include muted growth in the US market, lower demand for Pharma APIs impacting the Human Healthcare segment, and potential volatility in revenue recognition, as seen with a Rs 10 crore sales reversal this quarter. Global geopolitical tensions and supply chain issues also pose challenges.

Peer comparison

While specific peer results for Q1 FY27 are not detailed here, Advanced Enzyme operates in the specialty chemicals sector, facing competition from both domestic and international players. Its ability to innovate and maintain margins will be crucial.

Context metrics (time-bound)

• Revenue Q1 FY27: Rs 189.8 crore (2% YoY growth)
• EBITDA Q1 FY27: Rs 51 crore (10% YoY decline)
• PAT Q1 FY27: Rs 38.6 crore (5% YoY decline)
• EBITDA Margin: 27% (vs 30% in Q1 FY26)
• Inventory: Rs 190 crore (as of June 30, 2026)
• Working Capital Cycle: 125-138 days

What to track next

Investors will be closely watching the company's performance in the upcoming quarters, particularly the recovery of EBITDA margins to historical levels of 30-32%. Progress in the US market strategy and normalization of the sales reversal will also be key indicators.